Log book

Gene-editing: What’s next after CRISPR Cas9?

22 February 2017 | Alcim's articles

Alcimed, an innovation and new business consulting firm, is committed to supporting the pharmaceutical industry in observing emerging technologies such as gene editing technologies CRISPR Cas9 and the following generations. Gene editing describes the process of insertion, deletion or replacing a specific gene of the genome of an organism to introduce a new function or […]

Read more